Home › Research › Treatments
Rates of cognitive change in Alzheimer disease: observations across a decade of placebo-controlled clinical trials with donepezil
Jones RW, Schwam E, Wilkinson D, Waldemar G, Feldman HH, Zhang R, Albert K, Schindler R.. Alzheimer disease and associated disorders, 2009-10-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Treatment success in Alzheimer disease (AD) trials is generally based on benefits over placebo-treated controls. Consequently, variation in rates of decline among placebo-treated patients could impact outcomes from AD trials. In the present analyses, individual patient data [baseline Mini-Mental State Examination (MMSE): 10 to 26] were pooled from randomized, placebo-controlled studies of donepezil for AD conducted during the 1990s, and grouped by initiation year-group 1: 1990 to 1994; group 2: 1996 to 1999. Changes in MMSE and Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) were compared between groups 1 and 2 for placebo, and then between donepezil and placebo. Data were available from 3403 patients in 13 trials. Group 2 (post-1995) included patients with lower baseline MMSE scores, older patients, fewer males, more comorbidity, and more concomitant medications. MMSE decline by week 24 was significantly greater among group 1 (pre-1995) placebo patients versus group 2; a similar trend was observed with the ADAS-cog. Nevertheless, donepezil-mediated treatment effects were consistent over the decade of enrollment. These analyses suggest that patients are showing slower rates of cognitive decline in more recent trials compared with older trials, although having more comorbidities. This finding may have important potential implications for future clinical trial design.
What this study adds
Evidence grade: High
This is a pooled review of 3,403 participants. Pooled data from 13 donepezil trials found that placebo-treated patients declined more slowly in more recent trials than in older trials, while donepezil's treatment effects stayed consistent. This is about how trial results may vary over time, not about curing or preventing Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Jones, R. W., Schwam, E., Wilkinson, D., Waldemar, G., Feldman, H. H., Zhang, R., et al. (2009). Rates of cognitive change in Alzheimer disease: observations across a decade of placebo-controlled clinical trials with donepezil. Alzheimer disease and associated disorders. https://doi.org/10.1097/wad.0b013e31819cd4be
Vancouver
Jones RW, Schwam E, Wilkinson D, Waldemar G, Feldman HH, Zhang R, et al. Rates of cognitive change in Alzheimer disease: observations across a decade of placebo-controlled clinical trials with donepezil. Alzheimer disease and associated disorders. 2009. doi:10.1097/wad.0b013e31819cd4be. PMID: 19561444.
BibTeX
@article{jones2009-19561444,
author = {Jones, R. W. and Schwam, E. and Wilkinson, D. and Waldemar, G. and Feldman, H. H. and Zhang, R. and Albert, K. and Schindler, R.},
title = {{Rates of cognitive change in Alzheimer disease: observations across a decade of placebo-controlled clinical trials with donepezil}},
journal = {Alzheimer disease and associated disorders},
year = {2009},
doi = {10.1097/wad.0b013e31819cd4be},
pmid = {19561444},
url = {https://doi.org/10.1097/wad.0b013e31819cd4be}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- MMSE decline by week 24 was significantly greater among group 1 (pre-1995) placebo patients versus group 2; a similar trend was observed with the ADAS-cog.
- These analyses suggest that patients are showing slower rates of cognitive decline in more recent trials compared with older trials, although having more comorbidities.
Why it matters
Pooled data from 13 donepezil trials found that placebo-treated patients declined more slowly in more recent trials than in older trials, while donepezil's treatment effects stayed consistent. This is about how trial results may vary over time, not about curing or preventing Alzheimer's disease.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants3,403
- Evidence strengthHigh
How this study scored 56/100
Published in a peer-reviewed journal, and it is a meta-analysis pooling many studies. Scored zero for effect reported because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer disease and associated disorders) |
| Journal's citation record | 1 / 4 | Alzheimer Disease & Associated Disorders: journal h-index 131 (OpenAlex, 2026-10-29) |
| Study design | 12 / 12 | A meta-analysis pooling many studies (from PubMed type “Meta-Analysis”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2009 — within 20 year(s) of the newest study here |
| Sample size | 3 / 4 | 3,403 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | 3 / 7 | Cited 25 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.3 citations a year over 19 year(s) since 2009 |
| Impact for its field and year | 2 / 6 | Cited 2.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Rachel J. Schindler: h-index 27 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of British Columbia: institution h-index 1,424 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 6 institution(s) in 4 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 19561444) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 56 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.